From: Exercise-induced oxidative stress and melatonin supplementation: current evidence
Study, year | Participant characteristics | MT supplementation | Exercise measured | Results | Conclusions |
---|---|---|---|---|---|
Ochoa et al. 2011 [115] | Highly trained performing regular exercise amateur athletes (n = 20): experimental group (n = 10) supplemented with MT and control group (n = 10) receiving placebo | Oral intake of five tablets of 3 mg MT: one tablet two days before the exercise test, three tablets on the previous days and one tablet 1 h before beginning the test | High intensity constant run with several degrees of high effort on total distance 50 km with permanent climbing, altitude changing from 640 to 3393 m | Significantly increased blood levels of TNF-α, IL-6, IL-1Ra, urine 8-OHdG and isoprostane concentrations in both tested groups. Efficiently reduced lipid peroxides, TNF-α and 8-OHdG before and after exercise in the MT group vs placebo group | MT supplementation can reduce muscle damage via modulation of OS and preventing overexpression of proinflammatory cytokines |
Maldonado et al. 2012 [116] | 16 young male football players (experimental group n = 8, control group n = 8) | Experimental group treated with 6 mg MT, control group treated with placebo, 30 min prior to exercise | Acute sport training of high intensity (heart rate 135 beats per minute) | Exercise increased MDA in both groups, but significantly decreased in MT group after 60 min of training. Decreased triglyceride and increased serum IgA levels after training in MT group | Supplementation with MT in acute sport training decreased the OS generated by exercise, enhanced the serum TAS, and improved metabolism of lipids |
Leonardo-Mendonça et al. 2017 [122] | Randomized double-blind study of 24 resistance trained students (males). MT-treated men n = 12, placebo-treated men n = 12 (control group) | Experimental group supplemented with MT (100 mg daily, 30 min before bedtime for 4 weeks) | 8 sessions a week (about 10 h/week): 5 sessions-resistance training (3 sessions between 60–75% of maximal strength and 2 sessions between 80 and 90% of maximal strength), 2 sessions—weight training and 1 session—aerobic running | Increased ORAC levels by MT vs placebo after exercise. Reduced LPO, iNOS, GSSG/GSH and GPx/GRd ratios, CK, LDH, creatinine, cholesterol. Prevention against AOPP increase in MT group vs placebo group | MT enhanced potency of the endogenous antioxidant system, restored redox equilibrium state and protected against OS damage |
Ortiz-Franco et al. 2017 [117] | 14 male healthy athletes (age: 20–37 years) engaged in a 2-week randomized, double-blinded trial (MT-treated group and placebo-treated group) | 20 mg MT/day or placebo administered before exercise during the controlled study period (MT group) | Training program combined strength and high intensity interval trainings (6 sessions/week 60–75 min/day. \(V{\text{O}}_{2}^{\max }\): 70%, 90%) | Significantly increased MT level, TAC and GPx levels, decreased DNA damage in MT-treated group vs placebo group after 2-week exercise | MT treatment strengthens antioxidant state of athletes and protects DNA from damage caused by high intensity exercise |
Ziaadini et al. 2017 [118] | Two groups of sedentary women: involved in exercise training and treated with MT (n = 10) and only training (n = 10), mean age: 24.2 ± 1.03 and 23.4 ± 1.83 years, respectively | 3 mg/day MT supplementation before exercise training | 8-week (3 days/week) exercise training of increasing intensity and volume from 60 to 80% HRmax through 15 to 45 min | Significantly increased levels of MDA after long-lasting aerobic exercise training. Suppression of post-exercise increased MDA in the exercising and supplemented group | Supplementation with MT may decrease ROS levels, thus improve lipid profile |
Beck et al. 2018 [119] | 11 males moderately active, mean age: 24.18 ± 3.92 years | MT (6 mg) or placebo ingestion 30 min before exercise | Exercise on cycloergometer with initial workloads of 75 W and increments of 15 W each 3 min till exhaustion Maximal aerobic capacity 120.88 ± 18.78 W | A time to exhaustion significantly lower in placebo group compared to that with MT administered by approximately 19% | MT supplementation enhanced aerobic tolerance but was without effect on the biochemical and hematological parameters |
Brandenberger et al. 2018 [120] | Ten cyclists long-distance training, mean age 25.0 ± 4.0 years | 5 mg MT administered 15 min before time trial. Controls: placebo 15 min before time trial | 32.2 km cycling time trial performance at \(V{\text{O}}_{2}^{\max }\) 62.7 ± 6.8 (mL kg−1 min−1) on ergometer. Mean powers (190.4 ± 40.4 W and 190.0 ± 45.7 W, respectively) | No statistically significant differences between both groups in duration (completion times: MT group 64.94 ± 5.95 min, placebo group 65.26 ± 6.85) | Supplementation of MT did not exhibit of significant effect on performance in thermoneutral environment |
Czuczejko et al. 2019 [123] | Professional athletes: 47 football players, 19 rowers, 15 adults non-training males (control group) | 5 mg MT administered before sleep through 30 days in the preparatory period for athlete’s competition | Athletes: exercise on a cycle ergometer at 75% \(V{\text{O}}_{2}^{\max }\) | Decreased blood MT levels in footballers and rowers vs controls before MT intake. Increased serum MT level in footballers and in rowers after a 30-day MT intake. Reduced OS markers: MDA, IL-6, CRP, and low-density lipoproteins | Supplementation of MT in professional athletes during intense training may protect against the toxic action of ROS/RNS and inflammation |
Souissi et al. 2018 [121] | Eight healthy moderately trained male students, mean age: 21.8 ± 0.9 years | 6 mg MT supplementation or placebo at 09:00 a.m. in a randomized order 50 min before exercise | Running at 60% \(V{\text{O}}_{2}^{\max }\) for 45 min on a treadmill, starting at a speed of 8 km/h and increasing by 0.5 km/h after every minute | Exercise elevated inflammatory markers: CRP, LDH, ALAT, ASAT in both placebo or MT intake groups | MT ingestion before moderate prolonged submaximal exercise showed no anti-inflammatory action |
Cheikh et al. 2020 [124] | Randomized double-blind trial of 14 healthy-trained male athletes, mean age 154 ± 0.3 years | 10 mg MT or placebo ingestion (control) after vigorous late-evening exercise (10:00 p.m.) | Two-test sessions (separated at least one week) Running-Based Anaerobic Sprint Test at 8:00 p.m. and in the following morning (7:30 a.m.) | Reductions of: WBC, NE, LY, CRP, muscle and hepatic damage enzymes (CK, ASAD), LDH, MDA and homocysteine before and after strenuous exercise vs placebo group | MT intake after strenuous late-evening exercise diminished transient leukocytosis and protected against lipid peroxidation and muscle damage in teenage athletes |
Farjallach et al. 2019 [125] | 20 soccer players mean age 18.81 ± 1.3 years, MT group (n = 10), placebo group (n = 10) | Nocturnal oral MT (5 mg) or placebo ingestion in a double-blind manner | Intensive 6-day training-repeated sprint ability test: sprints 6 × 40 m with a 20 s of passive recovery between repetitions | Decreased resting OS markers: AOPP, leukocytosis and CK. Decreased post-exercise leukocytosis and markers of cellular damage (CK, ASAT, ALAT), increased GPx and GR activities in MT-treated group vs placebo group | Nocturnal MT intake during intensive training decreased OS, leukocytosis, cellular damage, and improved exercise performance |